Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MYK 224

Next Previous
Drug Profile

MYK 224

Alternative Names: BMS-986435; HCM-2; MYK 224

Latest Information Update: 11 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MyoKardia
  • Developer Bristol-Myers Squibb; MyoKardia
  • Class Cardiovascular therapies; Small molecules
  • Mechanism of Action Cardiac myosin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Heart failure; Hypertrophic cardiomyopathy

Most Recent Events

  • 01 Apr 2025 Bristol-Myers Squibb terminates the phase II MERCUTIO trial in Hypertrophic cardiomyopathy (Combination therapy, Monotherapy) in USA, Italy, Poland, Spain (PO), due to business objectives have changed (EudraCT2022-001292-14) (NCT05556343)
  • 19 Feb 2025 Bristol-Myers Squibb completes a phase I study (In volunteers) in US (PO, Tablet) (NCT06577259)
  • 11 Oct 2024 Bristol-Myers Squibb completes phase-I trial (In volunteers) in China (PO) (NCT06476821)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top